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ABSTRACT 
 
Schumacher, Alexandra Nicole.  Validation of the Six-Minute Walk Test for Predicting 
Peak Oxygen Consumption in Cancer Survivors.  Unpublished Master of Science 
Thesis, University of Northern Colorado, 2017. 
 
 
 Exercise improves cardiovascular function in cancer survivors (CS) suffering 
from treatment-related toxicities, such as decreased peak oxygen consumption (VO2peak).  
Establishing valid assessment protocols that determine VO2peak are essential for 
developing individualized exercise prescriptions for cancer rehabilitation programs.   The 
University of Northern Colorado Cancer Rehabilitation Institute (UNCCRI) has 
developed a valid cancer-specific VO2peak treadmill protocol to address this need.  The 
six-minute walk test (6MWT) is an exercise assessment used in many populations with 
chronic disease to predict VO2peak but it is not clear whether this test accurately assesses 
VO2peak in CS.  The 6MWT is simple, inexpensive, and representative of daily living 
activities.  Purpose:  To assess the validity of predicted VO2peak from the 6MWT 
compared to the UNCCRI treadmill protocol in CS.  Methods:  128 CS completed a 
UNCCRI treadmill protocol and a 6MWT one week apart in randomized order to obtain 
VO2peak (mL/kg/min).  VO2peak values from the UNCCRI treadmill protocol were 
compared against four common 6MWT VO2peak prediction equations.  Results:  All four 
6MWT prediction equations significantly (p < 0.001) underestimated VO2peak with 
predicted values ranging from 8.3 ± 3.8 to18.9 ± 3.0 mL/kg/min, while the UNCCRI 
treadmill protocol yielded a much higher value of 24.7 ± 7.4.  A positive strong 
  
iv 
correlation occurred between the UNCCRI treadmill protocol and one of the 6MWT 
prediction equations (r = 0.83) and a moderately strong correlation occurred between the 
UNCCRI treadmill protocol and another 6MWT equation (r = 0.70).  Maximum heart 
rates were significantly higher (p < 0.001) during the UNCCRI treadmill protocol 
compared to the 6MWT (150 ± 21 bpm vs. 109 ± 21 bpm).  Conclusion:  These findings 
suggest that the 6MWT is not a valid test for predicting VO2peak in CS due to its 
underestimation when using all four equations.  The UNCCRI treadmill protocol is a 
more accurate means of assessing VO2peak in CS in order to correctly prescribe an 
individualized exercise rehabilitation program.   
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CHAPTER I 
 
 
INTRODUCTION 
 
 
The number of people living beyond a cancer diagnosis in the United States is 
expected to rise to almost 19 million by 2024 (National Cancer Institute [NCI], 2016).  
Although cancer accounts for nearly one in four deaths, death rates are continuing to 
decline (NCI, 2016).  Due to an increase in the number of cancer survivors (CS), cancer 
is being viewed as a chronic illness requiring long term management and rehabilitation 
(Spence, Heesch, & Brown, 2010).  Cancer and its treatment can result in significant 
toxic side effects that impact the cardiopulmonary system.  Cardiotoxicity from 
chemotherapy leads to decreases in cardiac output and aerobic capacity, resulting in 
complications such as cardiomyopathy and left ventricular dysfunction (Carver et al., 
2007; Dy & Adjei, 2013; Eschenhagen et al., 2011; Yusuf, Razeghi, & Yeh, 2008).  
Treatment toxicities can be amplified in elderly CS because gerontological populations 
are more inclined to have increased rates of heart failure, coronary artery disease, 
arrhythmias, and left ventricular dysfunction (Sawhney, Sehl, & Naeim, 2005).  Many 
cancer rehabilitation programs exist to combat the physiological deficits from treatment 
through exercise interventions and are primarily focused on improving quality of life. 
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Exercise interventions are feasible in CS and a prescriptive plan leads to 
physiological improvement in areas such as muscular strength and aerobic capacity 
(Spence et al., 2010).  Peak oxygen uptake (VO2peak) is a measure of aerobic fitness that 
is consistently lower in CS compared to age-matched healthy individuals, and is often 
directly affected by the cytotoxic therapies that adversely impact the organ systems 
involved in exercise (Jones et al., 2011).  Exercise rehabilitation in CS has a positive 
impact on cardiorespiratory function and consequently increases VO2peak.  The results of 
a VO2peak assessment can provide clinicians with baseline information needed to 
prescribe the correct intensity of exercise as well as the correct progression throughout a 
cancer rehabilitation program.  Establishing valid assessment protocols that determine 
VO2peak are essential for developing individualized exercise prescriptions for cancer 
rehabilitation programs. 
 Maximal cardiopulmonary exercise testing (CPET) is considered the gold 
standard for measuring VO2peak, but it can be expensive, time consuming, and requires 
trained medical personnel to be present.  CPET has been found to be safe and feasible for 
those with advanced cancer (Jones et al., 2007) but some CPET protocols may be too 
difficult for CS to complete while others provide inaccurate results (Shackelford, Brown, 
Peterson, Schaffer, & Hayward, 2015).  The University of Northern Colorado Cancer 
Rehabilitation Institute (UNCCRI) developed an accurate and valid treadmill protocol to 
estimate VO2peak specifically for the cancer population.  The UNCCRI treadmill protocol 
has decreased grades and speeds to accommodate virtually any pulmonary, 
musculoskeletal, and cardiovascular dysfunctions caused by cancer treatments 
(Shackelford et al., 2015).  The UNCCRI treadmill protocol has more manageable 
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increases in intensity and provides a useful VO2peak value that allows for a complete an 
accurate exercise prescription (Shackelford et al., 2015).   
 The six-minute walk test (6MWT) is a submaximal exercise assessment used in 
many populations with chronic disease to predict VO2peak (American Thoracic Society, 
2002; Cahalin, Mathier, Semigran, Dec, & DiSalvo, 1996; Ross, Murthy, Wollak, & 
Jackson, 2010; Zugck et al., 2000), but it is not clear whether this test accurately assesses 
VO2peak in CS.  The 6MWT is favored in clinical populations because it is simple, 
inexpensive, and representative of activities of daily living.   
Statement of Purpose 
The purpose of this study is to evaluate the validity of the 6MWT for predicting 
VO2peak compared to the UNCCRI treadmill protocol in CS. 
Research Hypotheses 
H1 The VO2peak predicted from the 6MWT equations will be significantly 
lower than the VO2peak obtained from the UNCCRI treadmill protocol. 
 
H2 The predicted VO2peak from the multivariate 6MWT equations will have a 
higher correlation with the UNCCRI treadmill protocol VO2peak. 
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CHAPTER II 
 
REVIEW OF LITERATURE 
Introduction 
 Cancer is a disease characterized by abnormal cell growth and division.  There are 
over a hundred different types of cancer, the most common being breast, lung and 
bronchus, prostate, and colorectal (NCI, 2016).  Over 1.6 million new cases of cancer 
were predicted to be diagnosed in 2016 within the United States (ACS, 2016).  In the 
U.S., the lifetime risk of developing cancer is 42% for men and 38% for women (ACS, 
2016).  Even though death rates for the most common cancers are declining, cancer is the 
leading cause of death worldwide and accounts for nearly 1 of every 4 deaths (NCI, 
2016).  The number of people living beyond a cancer diagnosis in the U.S. is suspected to 
rise to almost 19 million by 2024 compared to 14.5 million in 2014 (NCI, 2016).  As the 
number of cancer survivors (CS) continues to increase, it is imperative that cancer 
rehabilitation programs utilize proper assessment and training techniques.  Exercise 
opposes the physiological decline in CS and an individual exercise prescription 
formulated from an initial assessment can help improve quality of life after a cancer 
diagnoses.    
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Cardiopulmonary Toxicity in Cancer Survivors 
 Cancer and its therapies for cancer can result in detrimental side effects that may 
significantly impact the cardiopulmonary system.  The most common cancer treatments 
include surgery, chemotherapy, and radiation therapy.  Chemotherapy drugs are 
especially known for eliciting severe toxic effects to the different physiological systems.  
Anthracyclines are one common class of chemotherapy agents that result in direct DNA 
damage through intercalation, interference with DNA repair through the inhibition of 
topoisomerase II, and the formation of free radicals.  This damage and disruption leads to 
the eventual apoptosis of cells (Arola et al., 2000; Monsuez, Charniot, Vignat, & Artigou, 
2010).  Radiation therapy leads to similar DNA damage and cell death.  Unfortunately, 
these treatments do not specifically target cancer cells and are concurrently toxic to 
healthy tissues resulting in detrimental symptoms (Eschenhagen et al., 2011).     
The toxic effects of chemotherapy have been extensively studied in relation to 
cardiac function.  Common cardiotoxicities of chemotherapy include arrhythmias, left 
ventricular dysfunction, myocardial ischemia, and cardiomyopathy with or without 
congestive heart failure (Carver et al., 2007; Dy & Adjei, 2013; Eschenhagen et al., 2011; 
Yusuf et al., 2008).  Cardiac damage from radiation therapy can lead to coronary artery 
disease (CAD), valve diseases, chronic pericardial disease, arrhythmias, conduction 
disturbances, cardiomyopathy, and carotid artery stenosis (Carver et al., 2007; DeSantis 
et al., 2014).  Thoracic radiotherapy can also damage the vascular network, resulting in 
reduced capillarization, decreased blood perfusion, anemia, and interstitial edema 
(Schneider, Dennehy, & Carter, 2003).  Deficiencies within the cardiovascular system of 
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supplying oxygen and nutrients to the major organ systems of the body can significantly 
reduce CS quality of daily living.   
The pulmonary system is a key component in healthy cardiorespiratory function.  
Radiotherapy to the chest often results in radiation pneumonitis, pulmonary fibrosis, and 
decreased pulmonary function (Carver et al., 2007).  These toxicities result in decreases 
in total and vital lung capacity, compromising the efficiency of oxygen diffusion and 
carbon dioxide removal (Schneider, Hsieh, Sprod, Carter, & Hayward, 2007).  Adverse 
effects from chemotherapy include interstitial injury with the impairment of alveolar 
capillary membranes (Marulli et al., 2010).  The incidence of radiation pneumonitis has 
been found to be five times greater with the addition of chemotherapy (Parashar et al., 
2011).  Palma et al. (2012) found that of those undergoing concurrent chemotherapy for 
non-small cell lung cancer (NSCLC), 30% are symptomatic of pneumonitis, increasing 
the rate of oxygen dependence.  The highest risk of radiation pneumonitis (>50%) occurs 
in CS greater than 65 years due to the likelihood of comorbid conditions (Palma et al., 
2012; Parashar et al., 2011).  A decrease in pulmonary reserve from these treatments may 
prevent patients from undergoing potential curative surgery to remove cancer (Sawhney 
et al., 2005).  Surgery for tumor removal in the lungs can also impact lung function 
adversely due to an increase in scar tissue (DeSantis et al., 2014).   
Guidelines for Physical Activity in Cancer Survivors 
Physical activity improves physiological functioning in healthy individuals and 
those managing chronic disease conditions (Stevinson, Lawlor, & Fox, 2004).  Physical 
activity of any kind can result in higher physical functioning, but an exercise prescription 
including 20-30 min of moderate intensity activity most days of the week was found to 
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have the greatest benefit for functional capacity in elderly (Brach, Simonsick, 
Kritchevsky, Yaffe, & Newman, 2004).  With advancements in early detection and 
improved treatments, cancer is being viewed more often as a chronic illness requiring 
long term management and rehabilitation (Spence et al., 2010).  Cancer treatments may 
lead to prolonged periods of inactivity which often lingers after treatment has ended 
(Burnham & Wilcox, 2002; Doyle et al., 2006; Midtgaard et al., 2013).  In CS, physical 
activity not only helps to manage any co-occurring chronic conditions, but helps prevent 
reoccurring cancer and secondary cancers (Doyle et al., 2006).  In women with breast 
cancer who followed the U.S. guidelines for physical activity, there was found to be a 26-
40% lower risk of death from reoccurrence (Holmes, 2005).  The area of physical 
rehabilitation utilizing an exercise prescription with aerobic and resistance components 
for CS is a growing field gaining plenty of momentum due to the support from research.  
Primary evidence from a systematic review citing 33 controlled trials concluded that 
physical activity through exercise interventions in CS leads to moderate increases in 
physical function, further resulting in increased activities of daily living (Stevinson et al., 
2004).  A similar systematic review of 10 studies with exercise interventions in CS 
concluded that exercise is feasible and provides a physiological improvement in several 
areas including strength and aerobic capacity during cancer rehabilitation (Spence et al., 
2010).  Recently, it was concluded that exercise training may help increase exercise 
capacity for people following lung resection in those diagnosed NSCLC (Cavalheri, 
Tahirah, Nonoyama, Jenkins, & Hill, 2014).     
In 2010, the American College of Sports Medicine (ACSM) hosted a roundtable 
discussion with several professionals in the cancer rehabilitation field.  They concluded 
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that exercise training during and after cancer treatment is safe and results in 
improvements in physical functioning, quality of life, and cancer related fatigue (Schmitz 
et al., 2010).  Physical activity guidelines have been established to accommodate other 
chronic health conditions, and the ACSM discussion determined the current guidelines of 
150 minutes per week of moderate activity or 75 minutes per week of vigorous activity, 
are appropriate for CS (Schmitz et al., 2010).  However, it was cautioned that exercise 
interventions in CS should be individualized and monitored by professionals in the field 
due to possible differences in treatments, pre-aerobic fitness, comorbidities, responses to 
treatment, and any other adverse effects (Schmitz et al., 2010; Schneider et al., 2007).     
Maximum and Peak Oxygen Consumption 
 VO2max is an assessment of cardiorespiratory fitness (CRF) measuring the ability 
of the cardiorespiratory system to utilize oxygen through intake and transport to skeletal 
muscle for ATP synthesis.  CRF is a powerful predictor of mortality in healthy 
populations.  VO2max is the product of maximum cardiac output and maximum arterial-
mixed venous oxygen difference, measured in absolute (L/min) or relative (mL/kg/min) 
terms.  VO2max declines with inactivity, age, and disease conditions, and is an important 
measure to monitor physiological status after an intervention.  A meta-analysis of 4884 
subjects showed that there is a decline in VO2max of approximately 10 mL/kg/min per 
decade (Fitzgerald, Tanaka, Tran, & Seals, 1997; Lakoski, Eves, Douglas, & Jones, 
2012).   
 A true measure of VO2max requires that an individual reach a Respiratory 
Exchange Ratio (RER) greater than 1.15, blood lactate levels greater than 8 mmol/L, and 
reach a plateau in oxygen consumption during maximal exercise testing measured by gas 
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analysis (ACSM, 2013).  When criteria are not reached, it is considered to be a 
measurement of peak oxygen consumption.  VO2peak is defined as the highest oxygen 
consumption measured during the last 30 seconds of a symptom limited exercise test and 
is likely a valid measure of VO2max during maximum effort (Day, Rossiter, Coats, 
Skasick, & Whipp, 2003; May et al., 2010; Zugck et al., 2000).  VO2peak also measures 
the ability of the cardiorespiratory system to deliver oxygen to skeletal muscle and the 
efficiency of the muscle to utilize the oxygen, however it is more reproducible than 
VO2max (Day et al., 2003).  In a study of 26 control subjects and 55 subjects with CAD, 
23% did not reach a plateau during VO2max testing (Eldridge, Ramsey-Green, Hossack, 
1986), and more recently only 17% of 71 subjects who exercised to their maximum limit 
of tolerance reached a plateau during testing (Day et al., 2003).  Cardiac responses 
between subjects who did or did not reach a plateau did not differ, concluding that 
VO2peak is a valid measure of maximum cardiac capacity (Eldridge et al., 1986).  VO2peak 
has gained acceptance as a measure of VO2max in clinical populations (Cote, Pinto-Plata, 
Kasprzyk, Dordelly, & Celli, 2007).     
VO2peak is the measure often used in CS to assess CRF (May et al., 2010; Schmidt, 
Vogt, Thiel, Jager, & Banzer, 2013) and greater CRF is associated with a reduced risk of 
dying from cancer (Doyle et al., 2006; Jones et al., 2011; Klika, Callahan, & Drum, 
2009; Peel et al., 2009).  VO2peak is consistently lower in CS, often directly a result of the 
cytotoxic therapies that adversely impact the organ systems involved in exercise (Jones et 
al., 2011).  Smoot, Johnson, Duda, Krasnoff, & Dodd (2012) found the mean VO2peak in 
120 breast CS to be 25 ml/kg/min, which falls below the 30th percentile for published 
healthy norms.  Another study found the mean VO2peak value for 346 pre-surgical patients 
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with NSCLC to be 16 ± 0.4 mL/kg/min, equivalent to only 36% of sex and age matched 
individuals (Loewen et al., 2007).  Burnett, Kluding, Porter, Fabian, & Klemp (2013) 
found that 77% of their study participants with breast cancer had a VO2max below the 20
th 
percentile for norms.   
Exercise rehabilitation in CS has proven to have a positive impact on 
cardiorespiratory function and thus increases VO2peak.  A recent study found a significant 
improvement in VO2peak of over 3 mL/kg/min after a 3-month exercise intervention 
(Repka et al., 2014).  A meta-analysis of pooled data from six different exercise 
intervention studies in CS (N=571) concluded that there was a significant increase in 
VO2peak of almost 3 mL/kg/min, compared with a decrease in VO2peak of -1 mL/kg/min in 
those CS who didn’t receive an exercise intervention (Jones et al., 2011).  In a different 
intervention study it was concluded that physical activity was able to blunt a decline in 
VO2max by 8% (Courneya et al., 2007), and similar results have been observed by others 
(Midtgaard et al., 2013; Quist et al., 2006; Schneider et al., 2007).  Contrary to the 
previous results, 37 CS of multiple myeloma underwent a three-month exercise 
intervention with no significant change in oxygen consumption (p = 0.057) (Groeneveldt 
et al., 2013).  There was a positive improvement in VO2peak, but the result was not 
significant.  This was likely due to the intensity of the intervention being less than (50% 
HRR) other similar studies (Groeneveldt et al., 2013).      
Exercise Testing in Cancer Survivors 
Cardiopulmonary Exercise Testing  
Maximal cardiopulmonary exercise testing (CPET) is considered the “gold 
standard” for measuring VO2max (Burnett et al., 2013; Turner, Eastwood, Cecins, Hillman 
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& Jenkins, 2004).  CPET requires gas analysis with a metabolic cart, is expensive, time 
consuming, and requires trained medical personnel to be present, especially in clinical 
populations.  The American Thoracic Society (ATS) defines formal CPET as a test to 
provide a global assessment of the exercise response and an objective determination of 
functional capacity or impairment.  It can determine the appropriate intensity needed to 
perform prolonged exercise and define underlying pathophysiologic mechanisms (ATS, 
2002).   
During CPET testing, workload is increased progressively until symptoms force 
discontinuation of the test (Cote et al., 2007).  CPET can be conducted using gas analysis   
during various treadmill, step, and cycle ergometer protocols.  Validated treadmill 
protocols are safe, reliable, and the ACSM provides accurate prediction equations to 
estimate VO2max clinically using the last stage of completion when gas analysis is not 
available (ACSM, 2013).  VO2max has been shown to be 5-10% higher when a treadmill 
protocol is used compared with a cycle ergometer test protocol (Bruce, Kusumi, & 
Hosmer, 1973; Cahalin et al., 1996; Jones et al., 2007).   
Exercise performance can be greatly reduced in patients with heart failure and 
similar diseases affecting cardiopulmonary systems (Zugck et al., 2000).  CPET is a 
powerful tool that can provide information on the nature of cardiorespiratory response to 
exercise in chronic disease populations (Cote et al., 2007).  Ramp protocols are 
commonly utilized in elderly or clinical populations with more limited capacity.  These 
protocols can be less intimidating because they increase speed and grade continuously to 
reach peak cardiovascular responses (Bader, Maguire, & Balady, 1999).  The lower the 
workload increments, the less likely that tests will be terminated due to other factors 
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other than maximum cardiopulmonary responses, thus reducing errors of estimation for 
VO2max (Shackelford et al., 2015).  Reliable, accurate, and valid CPET are of utmost 
importance in clinical populations in order to optimize rehabilitation programs, prescribe 
individual training intensities, and to improve quality of life for patients (De Backer et 
al., 2007; Gayda, Temfemo, Choquet, & Ahmaidi, 2004). 
Promising research has led to an increase in cancer rehabilitation programs, yet 
there are few standards for assessing exercise capacity in CS (Stubblefield, 2013).  
Clinics assessing CS may choose to use a submaximal test due to impaired balance and 
coordination even when CPET has been found to be safe and feasible for those with 
advanced cancer (Jones et al., 2007; Klika et al., 2009).  Like other healthy and chronic 
disease populations, CPET in CS is very important for screening, exercise prescription 
and determination of exercise capacity (Jones et al., 2007).   
The University of Northern Colorado Cancer Rehabilitation Institute (UNCCRI) 
has developed an accurate and valid treadmill protocol to estimate VO2peak in a cancer 
specific population.  CPET protocols for healthy or other populations may be too difficult 
for CS to complete safely, therefore the UNCCRI protocol has decreased grades and 
speeds to accommodate any pulmonary, musculoskeletal, and cardiovascular 
dysfunctions caused by cancer treatments (Shackelford et al., 2015).  Both CS and 
apparently healthy subjects performed a Bruce treadmill protocol and the UNCCRI 
treadmill protocol with and without gas analysis.  The correlation for all participants 
between VO2peak with and without gas analysis for the UNCCRI protocol was r = 0.90.  
These results suggest that ACSM’s walking/running equations are valid for determining 
VO2peak in CS and gas analysis is not required with this protocol.  No CS had any adverse 
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effects when completing any of the protocols, indicating CS can complete a VO2peak test 
safely.  In CS, heart rates during the Bruce protocol were significantly lower at 
termination than the UNCCRI protocol.  CS often terminated the Bruce protocol due 
more to muscle fatigue than actual cardiorespiratory effects.  The Bruce has been shown 
to overestimate VO2peak and thus will yield inaccurate prescriptions that could hinder CS 
if too intense (Bader et al., 1999; Shackelford et al., 2015).   The UNCCRI protocol is 
more appropriate due to smaller work increments, which yield a more accurate 
relationship between oxygen supply and demand (Jones et al., 2007; Shackelford et al., 
2015).  Establishing accurate VO2peak values for CS is the first step in the process of 
designing and implementing an accurate exercise prescription.     
There are several instances why maximal testing may not be performed.  CPET 
may not be widely available to clinics outside of hospitals due to expense and the 
availability of medical personnel, and may be contraindicated in severely limited 
populations (Burnett et al., 2013; Cahalin et al., 1996; Guyatt et al., 1985).  It may be 
perceived that CPET places an unwarranted burden on patients due to the test being 
exhaustive, thus bringing safety into question.  In patients with chronic obstructive 
pulmonary disease (COPD), it was found that symptoms interfere long before a possible 
VO2peak could be achieved (Cote et al., 2007).  Studies have reported that the gas analysis 
apparatus may be extremely uncomfortable for patients and could yield inaccurate results 
(Shackelford et al, 2015; Zugck et al., 2000).  CPET may also be impractical for 
populations who need frequent assessments (Green, Watts, Rankin, Wong, & Driscoll, 
2001).   
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For these reasons, submaximal testing is often chosen in lieu of a maximal test in 
clinical environments without access to formal CPET.  Submaximal testing allows for a 
measure of sustainable cardiovascular response to exercise capacity safely without 
maximizing heart rate (Burnett et al., 2013).  Submaximal testing at 85% age predicted 
heart rate max shows a strong correlation (r = 0.89) with predicted VO2max (Burnett et al., 
2013).  May et al. (2010) concluded that there was not a significant difference (p = 0.1) 
between VO2max measured from CPET versus VO2max estimated from submaximal 
workload and a heart rate response greater than 140 bpm could serve as an alternative to 
maximal testing.  However, it has been demonstrated that heart rate can vary 
substantially during submaximal workloads and it is important to assess patients based on 
individual needs and capacity (De Backer et al., 2007).  Therefore, CPET is still the 
preferred protocol for initial assessments, particularly for prescribing an accurate exercise 
prescription during rehabilitation.  However, submaximal testing allows for more 
frequent assessments to monitor clinical progress.   
The Six-Minute Walk Test 
One of the most utilized submaximal tests in clinical populations is the six-minute 
walk test (6MWT).  The 6MWT was first developed as a twelve-minute walk test but 
was further adapted to six minutes for more limited pulmonary populations.  It has since 
been used in cardiac populations and rehabilitation settings (Enright, 2003; Guyatt et al., 
1985).  The 6MWT is a quick, inexpensive measure of physical function.  It can be 
performed with frail, elderly, and severely limited patients (Enright & Sherrill, 1998; 
Guyatt et al., 1985).  It is favored in clinical populations because it is less expensive, 
safe, and easy to administer.  A walking test is also considered to be more reflective of 
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daily living activities in these clinical populations.  A protocol for conducting the 6MWT 
has been standardized by the ATS.  The test has high intra class correlation values greater 
than 0.80 and a practice test is not needed (Sciurba et al., 2003; Steffen, Hacker, & 
Mollinger, 2002; Weiss, 2000; Zugck et al., 2000).     
Research in chronic disease populations concludes that the walk test is a valid test 
for monitoring exercise capacity in those with lower VO2peak.  In patients with COPD, 
interstitial lung disease, and pulmonary hypertension, VO2peak measured during the 
6MWT is not significantly different than VO2peak during CPET (Blanco et al., 2010; 
Fujino et al., 2015; Hill et al., 2012; Starobin et al., 2006; Turner et al., 2004).  In elderly 
subjects with CAD, VO2peak during the 6MWT was not significantly different than CPET 
VO2peak (14.3 ± 2.9 vs 13.4 ± 2.7 mL/kg/min) (Gayda et al., 2004).  Hill et al. (2012) 
found no significant differences between VO2peak (p = 0.31) and peak heart rate (p = 0.58) 
values when comparing the 6MWT, shuttle walk tests, and a cycle CPET in those with 
moderate COPD.  Similar findings have been observed in those with heart failure and 
cardiomyopathy (Faggiano, D’Aloia, Gualeni, Brentana, & Cas, 2004; Gayda et al., 
2004; Zugck et al., 2000).   
  Lipkin, Scriven, Crake, & Poole-Wilson (1986) were the first to demonstrate a 
curvilinear relationship between VO2peak and distance walked during the 6MWT.  The 
findings documented that for a VO2peak over 20 mL/kg/min determined by CPET, 
distance walked on the test varied.  Since then several studies have confirmed a moderate 
to high positive correlational relationship between the 6MWT distance and VO2peak in 
clinical populations (Cahalin et al., 1996; Faggiano, D’Aloia, Gualeni, Lavatelli, & 
Giordano, 1997; Faggiano et al., 2004; Gayda et al., 2004; Guazzi, Dickstein, Vicenzi, & 
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Arena, 2009; Zugck et al., 2000).  Cahalin et al. (1996) developed several prediction 
equations from this linear relationship with distance to predict VO2peak in patients with 
heart failure.  These prediction equations are based not only on distance, but also on 
multivariate factors like height and weight to help reduce the variability seen in 
individual subjects.   Ross et al. (2010) reviewed several studies and determined a valid 
equation to predict VO2peak from 1083 patients with diverse cardiopulmonary diagnoses.  
Other studies concluded similar findings to Lipkin et al. (1986) that the test becomes less 
sensitive with greater functional capacity (Deboeck, Muylem, Vachiery, & Naeije, 2014; 
Fujino et al., 2015; Jehn et al., 2009; Schmidt et al., 2013;)   
Given the compromised state of CS, clinics may opt for submaximal protocols 
like the 6MWT.  Kasymjanova et al. (2009) used the 6MWT to determine which patients 
might have less adverse physiological effects during chemotherapy treatment.  They 
found that those who walked a distance greater than 400m would likely have less 
physiological side effects from treatment.  The researchers found that after two cycles of 
chemotherapy, the six-minute walk distance significantly declined by more than 54m in 
29% of the subjects.  Over half of the patients dropped out of the study due to the 
consequences of chemotherapy.  To our knowledge, Schmidt et al. (2013) are the only 
researchers to evaluate the 6MWT and its correlation with VO2peak in CS.  They chose a 
cycle CPET to determine VO2peak because it was considered safer and there was no need 
for time consuming treadmill familiarization trials.  They found the 6MWT to be reliable 
as an assessment tool and found a correlation between distance and VO2peak to be 
moderate (r = 0.67).  The average distance walked was 594 ± 81 m and subjects walked 
with an intensity averaging 86 ± 10% of their estimated heart rate maximum.  The 
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researchers concluded the 6MWT was a valid test for determining functional capacity, 
but may not be sensitive enough to detect intervention related effects in patients with 
early stage disease.  To our knowledge no studies have considered the validity of 
established VO2peak prediction equations in cancer survivors.     
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CHAPTER III 
 
 
METHODOLOGY 
Subjects 
 A total of 128 subjects participated in this study.  All participants were cancer 
survivors (CS) enrolled in the University of Northern Colorado Cancer Rehabilitation 
Institute’s (UNCCRI) program.  Inclusion criteria for participants included 1) diagnosed 
with cancer, 2) at least 18 years of age, and 3) no history of stroke, chronic respiratory 
difficulties, or severe arterial hypertension (resting systolic blood pressure > 200 mmHg, 
resting diastolic blood pressure > 110, or both).  Participants were referred to UNCCRI 
and their medical records were obtained from the referring oncologist or primary care 
physician.  Participants signed an informed consent upon entering the program at 
UNCCRI agreeing to participate in research within the institute.  From 2015-2016, 
participants entering the UNCCRI program enrolled in and completed this study.  
Existing clients already in the program were recruited via flyers within the clinic for 
participation.  Participants may have been receiving chemotherapy (N = 21), radiation 
therapy (N = 3), a combination of chemotherapy and radiation (N = 8), or 
immunotherapy (N = 3) during participation.  Prior to participation, a detailed 
explanation was given about the study protocols. 
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Exclusion criteria for participants included 1) history of congestive heart failure, 
2) history of myocardial infarction, 3) chronic lung disease, 4) asthma, 5) significant 
ambulatory issues, 6) history of coughing up blood, 7) fainting, and 8) epilepsy. 
Safety was ensured by having trained Cancer Exercise Specialists (CES) supervising each 
protocol.  The protocols used in the study were approved by the University of Northern 
Colorado’s Institutional Review Board (see Appendix B).   
Experimental Design 
 The purpose of this study was to assess the validity of predicted VO2peak from the 
6MWT compared to the validated UNCCRI treadmill protocol in CS.  Participants 
underwent a thorough initial interview and physician clearance to assure they could 
complete VO2peak testing.  Participants who qualified for the study completed one 
UNCCRI treadmill protocol and one 6MWT one week apart in randomized order.    
University of Northern Colorado Cancer Rehabilitation  
Institute Treadmill Protocol 
 The UNCCRI treadmill protocol appears in detail in Table 1 and in Appendix C.  
There are 21 total stages, each stage lasts a duration of one minute.  Stage 0 starts at 1 
mph and a 0% incline.  Speed increased by no more than 0.5 miles per hour (mph) 
between stages 0-6 and an incline of 2% was not observed until stage 4.  Starting after 
the 5th stage, speed was increased by 0.1 mph and grade increased by 1% after each 
completed stage.   
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Table 1 
The University of Northern Colorado Cancer Rehabilitation Protocol   
Stage   Speed   Grade   Time   
0   1.0mph   0%   1 min   
1   1.5mph   0%   1 min   
2   2.0mph   0%   1 min   
3   2.5mph   0%   1 min   
4   2.5mph   2%   1 min   
5   3.0mph   2%   1 min   
6   3.3mph   3%   1 min   
7   3.4mph   4%   1 min   
8   3.5mph   5%   1 min   
9   3.6mph   6%   1 min   
10   3.7mph   7%   1 min   
11   3.8mph   8%   1 min   
12   3.9mph   9%   1 min   
13   4.0mph   10%   1 min   
14   4.1mph   11%   1 min   
15   4.2mph   12%   1 min   
16   4.3mph   13%   1 min   
17   4.4mph   14%   1 min   
18   4.5mph   15%   1 min   
19   4.6mph   16%   1 min   
20   4.7mph   17%   1 min   
Cool Down       **   0%   ***   
  
21 
 
 
 
Resting blood pressure (BP), resting heart rate (HR), blood oxygen saturation 
(SpO2), and body weight (kg) were measured before the treadmill test.  Blood pressure 
was measured manually by auscultation a sphygmomanometer and stethoscope, HR was 
determined using a Polar® Heart Rate Monitor, SpO2 was measured using a Clinical 
Guard® pulse oximeter, and body weight was measured by the InBody 770®.  Three 
Clinical Cancer Exercise Specialists conducted the treadmill test for safety.  One CES 
changed the grade and/or speed every minute dependent on the stage of the protocol, as 
well as recorded vital information.  One CES recorded BP every three minutes, while one 
CES stood behind the participant during the duration of the protocol for spotting and 
safety and to monitor any safety concerns. 
Before each test participants were given the following instructions: 1) BP will be 
taken every three minutes by a CES, 2) another CES will be recording HR and SpO2 and 
changing speed and/or grade every minute, 3) a pulse oximeter will be placed on your 
finger for the duration of the test to monitor oxygen saturation every minute, 4) a CES 
will also stand behind you during the duration of the test for your safety and to ensure 
proper placement on the treadmill belt, 5) we ask that you push yourself to maximum 
exertion and although you may stop at any time, we would like you to reach the point 
where you feel that you can’t physically continue, 6) we recommend that you do not use 
the handrails unless you feel it is absolutely necessary, 7) you must choose to use or not 
use the handrails for the entire protocol, 8) after maximal exertion a cool down phase at a 
lower speed and grade will be initiated until vitals reach near-resting measures. 
The test ended when the participant reached his or her perceived maximum 
exertion or could not continue further.  The test concluded when the participant verbally 
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expressed they had reached their maximum rate of perceived exertion (RPE) using a 
modified Borg RPE, or when the participant physically grabbed onto the handrails to 
signal the end of the test.  Once the participant indicated they had reached maximum 
effort, the cool down phase was initiated.  When the participant’s vitals were close to 
resting vitals and the participant indicated that they felt safe to get off the treadmill, the 
treadmill was stopped.  Final vitals were recorded, including the maximum HR reached.  
The duration of the test until maximum exertion and the final completed stage was also 
recorded.  HR and SpO2 continued to be recorded every minute, while BP and RPE 
continued to be recorded every three minutes.  When the participant vitals were close to 
resting levels and the participant indicated that they felt safe to get off the treadmill, the 
treadmill was stopped.  Final vitals were recorded, including when the maximum HR 
reached.  The duration of the test until maximum exertion and the final completed stage 
was also recorded. 
 The American College of Sports Medicine running and walking equations were 
used to calculate VO2peak from the last completed stage of the protocol.  If the participant 
was walking at maximum exertion the following equation was used: VO2peak 
(mL/kg/min) = (0.1 x S) + (1.8 x S x G) + 3.5.  The variable S is the speed in meters/min 
and G is the percentage of grade in decimal form.  If the participant was running at 
maximum exertion the following equation was used: VO2peak = (0.2 x S) + (0.9 x S x G) 
+ 3.5.  If the participant was using the handrails during the protocol the following 
equation was used: VO2peak= 0.694 x [the ACSM walking/running value from above] + 
3.33 (ACSM, 2013).       
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The Six Minute Walk Test Protocol 
 The 6MWT protocol appears in Appendix D.  The 6MWT was conducted under 
the guidelines of the American Thoracic Society (ATS).  The 6MWT took place in a 
12.6-meter-long hallway at the UNCCRI.  Prior to the 6MWT, participants performed a 
pulmonary assessment using a MIR Spirolab III® portable desktop spirometer to assess 
force vital capacity (FVC) and forced expiratory capacity (FEV1) of the lungs.  Two 
CES’s supervised the test to ensure participant safety. 
 At the beginning of the test each participant was given the following instructions: 
1) walk up and down the hallway for six minutes, reaching the colored dot at each end of 
the hallway, 2) try to walk as far as possible in that six-minute time frame, and 3) at any 
time you can stop to rest or sit in one of the chairs, but we ask that you keep walking as 
soon as you feel able.  The participants were asked to walk alone unless gait imbalances 
required them to have a CES near to assist them.  At every minute, participants were told 
the time remaining and a standard verbal encouragement such as “Great job” was given.  
One CES kept track of the time on a stopwatch and placed a mark on the data collection 
sheet every time the participant completed one length of the hallway.  At the end of the 
test, participants were asked to stop where they were and a CES marked on the wall 
where they had stopped.  The CES measured the partial distance the participant had 
covered from the end of the hall to the spot on the wall with a meter stick.  This value 
was added to the total distance of lengths completed to ensure a precise measurement of 
distance covered.  At the end of the test HR, BP, RPE and SpO2 values were recorded 
immediately by a CES.    
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The distance and other variables were used to calculate predicted VO2peak from 
four well established prediction equations: 1) VO2peak = 0.03 x distance (m) + 3.98 
(Cahalin et al., 1996), 2) VO2peak = 0.02 x distance (m) – 0.191 x age (yrs) – 0.07 x 
weight (kg) + 0.09 x height (cm) +0.26 x (RPP x 10^-3) + 2.45 (Cahalin et al., 1996), 3) 
VO2peak = 0.02 + distance (m) - 0.14 x age (yrs) - 0.07 x weight (kg) + 0.03 x height (cm) 
+ 0.23 x (RPP x 10^-3) + 0.10 x FEV1(L) – 1.19 x FVC (L) + 7.77 (Cahalin et al., 1996), 
and 4) VO2peak = 4.948 + 0.023 x distance (m) (Ross et al., 2010).  
Statistical Analysis 
 A power analysis was ran using the statistical program G-power (Version 3.1) 
prior to the study to determine the appropriate sample size for significance.  For both 
protocols a repeated measures ANOVA was utilized to examine the differences in 
VO2peak obtained by the UNCCRI treadmill protocol to against VO2peak values determined 
by the four 6MWT prediction equations.  It was assumed that 1) the dependent variable 
of VO2peak was continuous, 2) the tests were matched pairs, 3) there were no significant 
outliers, and 4) there was a normal distribution.  Paired t-tests were utilized to test the 
differences between HR and SBP between the UNCCRI protocol and the 6MWT 
protocol.  A Pearson r-correlation between the UNCCRI treadmill and 6MWT equations 
1-4 to determine the strength of the relationship in VO2peak.  Significance was set to p < 
0.05.  All statistics were derived using the Statistical Package for the Social Sciences 
software package (SPSS, Chicago, IL). 
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CHAPTER IV 
 
MANUSCRIPT 
Introduction 
 The number of people living beyond a cancer diagnosis in the United States is 
expected to rise to almost 19 million by 2024 (NCI, 2016).  Although cancer accounts for 
nearly one in four deaths, death rates are continuing to decline (NCI, 2016).  Due to an 
increase in the number of cancer survivors (CS), cancer is being viewed as a chronic 
illness requiring long term management and rehabilitation (Spence et al., 2010).  Cancer 
and its treatment can result in significant toxic side effects that impact the 
cardiopulmonary system.  Cardiotoxicity from chemotherapy leads to decreases in 
cardiac output and aerobic capacity, resulting in complications such as cardiomyopathy 
and left ventricular dysfunction (Carver et al., 2007; Dy & Adjei, 2013; Eschenhagen et 
al., 2011; Yusuf et al., 2008;).  Treatment toxicities can be amplified in elderly CS 
because gerontological populations are more inclined to have increased rates of heart 
failure, coronary artery disease, arrhythmias, and left ventricular dysfunction (Sawhney 
et al., 2005).  Many cancer rehabilitation programs exist to combat the physiological 
deficits from treatment through exercise interventions and are primarily focused on 
improving quality of life. 
 Exercise interventions are feasible in CS and a prescriptive plan leads to 
physiological improvement in areas such as muscular strength and aerobic capacity 
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(Spence et al., 2010).  Peak oxygen uptake (VO2peak) is a measure of aerobic fitness that 
is consistently lower in CS compared to age-matched healthy individuals, and is often 
directly affected by the cytotoxic therapies that adversely impact the organ systems 
involved in exercise (Jones et al., 2011).  Exercise rehabilitation in CS has a positive 
impact on cardiorespiratory function and consequently increases VO2peak.  The results of 
a VO2peak assessment can provide clinicians with baseline information needed to 
prescribe the correct intensity of exercise as well as the correct progression throughout a 
cancer rehabilitation program.  Establishing valid assessment protocols that determine 
VO2peak are essential for developing individualized exercise prescriptions for cancer 
rehabilitation programs. 
 Maximal cardiopulmonary exercise testing (CPET) is considered the gold 
standard for measuring VO2peak, but it can be expensive, time consuming, and requires 
trained medical personnel to be present.  CPET has been found to be safe and feasible for 
those with advanced cancer (Jones et al., 2007) but some CPET protocols may be too 
difficult for CS to complete while others provide inaccurate results (Shackelford et al., 
2015).  The University of Northern Colorado Cancer Rehabilitation Institute (UNCCRI) 
developed an accurate and valid treadmill protocol to estimate VO2peak specifically for the 
cancer population.  The UNCCRI treadmill protocol has decreased grades and speeds to 
accommodate virtually any pulmonary, musculoskeletal, and cardiovascular dysfunctions 
caused by cancer treatments (Shackelford et al., 2015).  The UNCCRI treadmill protocol 
has more manageable increases in intensity and provides a useful VO2peak value that 
allows for a complete an accurate exercise prescription (Shackelford et al., 2015).   
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 The six-minute walk test (6MWT) is a submaximal exercise assessment used in 
many populations with chronic disease to predict VO2peak (American Thoracic Society, 
2002; Cahalin et al., 1996; Ross et al., 2010; Zugck et al., 2000), but it is not clear 
whether this test accurately assesses VO2peak in CS.  The 6MWT is favored in clinical 
populations because it is simple, inexpensive, and representative of activities of daily 
living.  The purpose of this study was to evaluate the validity of the 6MWT for predicting 
VO2peak compared to the UNCCRI treadmill protocol in CS.  
Methods 
Subjects 
 A total of 128 subjects participated in this study.  All participants were CS 
enrolled in UNCCRI’s cancer rehabilitation program.  Participants were referred to 
UNCCRI and their medical records were provided by their oncologist or primary care 
physicians.  Upon entering the program at UNCCRI, participants signed an informed 
consent approved by the University of Northern Colorado’s Institutional Review Board 
agreeing to participate in research within the institute.  From 2015-2016, participants 
entering the UNCCRI program enrolled in and completed this study.  Existing clients 
already in the program were recruited via flyers within the clinic for participation.  
Participants were excluded if they had a history of congestive heart failure, myocardial 
infarction, chronic lung disease, asthma, significant ambulatory issues, history of 
coughing up blood, fainting, or epilepsy. 
Experimental Design 
 Participants who qualified for the study completed one UNCCRI treadmill 
protocol and one 6MWT one week apart in randomized order.  Resting blood pressure 
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(BP), resting heart rate (RHR), blood oxygen saturation (SpO2), height (cm), and body 
weight (kg) were measured before each test.  Blood pressure was measured manually by 
auscultation, HR was determined using a Polar® Heart Rate Monitor, SpO2 was 
measured using a Clinical Guard® pulse oximeter, height was measured by the BSM170 
stadiometer, and body weight was measured by the InBody 770®.  Clinical Cancer 
Exercise Specialists (CES) ensured participant safety throughout both protocols.  Five 
different VO2peak values were compared using a repeated measures ANOVA: 1) VO2peak 
obtained from the UNCCRI protocol, and 2) VO2peak values derived from four well-
documented 6MWT prediction equations. 
University of Northern Colorado  
Cancer Rehabilitation Institute  
Treadmill Protocol 
 
 There are 21 total stages of the UNCCRI treadmill protocol, each stage lasting 
one minute.  Speed and/or grade was increased at the completion of each stage.  Details 
of the protocol appear in Table 1.  Participants were informed that they would be 
completing a UNCCRI Treadmill VO2peak protocol and could terminate the test at any 
time, but were encouraged to continue to their maximum effort.   
 Before each test, participants were given the following instructions: 1) BP will be 
taken every three minutes by a CES, 2) another CES will be recording HR and SpO2 and 
changing speed and/or grade every minute, 3) a pulse oximeter will be placed on your 
finger for the duration of the test to monitor oxygen saturation every minute, 4) a CES 
will also stand behind you during the duration of the test for your safety and to ensure 
proper placement on the treadmill belt, 5) we ask that you push yourself to maximum 
exertion and although you may stop at any time, we would like you to reach the point 
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where you feel that you can’t physically continue, 6) we recommend that you do not use 
the handrails unless you feel it is absolutely necessary, 7) you must choose to use or not 
use the handrails for the entire protocol, 8) after maximal exertion a cool down phase at a 
lower speed and grade will be initiated until vitals reach near-resting measures. 
 The test ended when the participant reached his or her perceived maximum 
exertion or could not continue further.  The test concluded when the participant verbally 
expressed when they had reached their maximum rate of perceived exertion (RPE) using 
a modified Borg RPE, or when the participant physically grabbed onto the handrails to 
signal the end of the test.  Once the participant indicated they had reached maximum 
effort, the cool down phase was initiated.  When the participant’s vitals were close to 
resting values and the participant indicated that they felt safe to get off the treadmill, the 
treadmill was stopped.  Final vitals were recorded, including when the maximum HR was 
reached.  The duration of the test until maximum exertion and the final completed stage 
were also recorded. 
 The American College of Sports Medicine (ACSM) running and walking 
equations were used to calculate VO2peak from the last completed stage of the protocol.  If 
the participant was walking at maximum exertion the following equation was used: 
VO2peak (mL/kg/min) = (0.1 x S) + (1.8 x S x G) + 3.5.  The variable S is the speed in 
meters/min and G is the percent grade in decimal form.  If the participant was running at 
maximum exertion the following equation was used: VO2peak = (0.2 x S) + (0.9 x S x G) 
+ 3.5.  If the participant was using the handrails during the protocol the following 
equation was used: VO2peak = 0.694 x [the ACSM walking/running value from above] + 
3.33 (ACSM, 2013).       
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Table 2 
The University of Northern Colorado Cancer Rehabilitation Protocol   
Stage   Speed   Grade   Time   
0   1.0mph   0%   1 min   
1   1.5mph   0%   1 min   
2   2.0mph   0%   1 min   
3   2.5mph   0%   1 min   
4   2.5mph   2%   1 min   
5   3.0mph   2%   1 min   
6   3.3mph   3%   1 min   
7   3.4mph   4%   1 min   
8   3.5mph   5%   1 min   
9   3.6mph   6%   1 min   
10   3.7mph   7%   1 min   
11   3.8mph   8%   1 min   
12   3.9mph   9%   1 min   
13   4.0mph   10%   1 min   
14   4.1mph   11%   1 min   
15   4.2mph   12%   1 min   
16   4.3mph   13%   1 min   
17   4.4mph   14%   1 min   
18   4.5mph   15%   1 min   
19   4.6mph   16%   1 min   
20   4.7mph   17%   1 min   
Cool- Down     **   0%   ***   
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The Six Minute Walk Test Protocol 
 The 6MWT was conducted under the guidelines of the American Thoracic 
Society (ATS).  The 6MWT took place in a 12.6-meter-long hallway at the UNCCRI.  
Prior to the 6MWT, participants performed a pulmonary assessment using a MIR 
Spirolab III® portable desktop spirometer to determine force vital capacity (FVC) and 
forced expiratory capacity (FEV1) of the lungs.  Two CES’s supervised the test to ensure 
participant safety. 
 At the beginning of the test each participant was given the following instructions: 
1) walk up and down the hallway for six minutes, reaching the colored dot at each end of 
the hallway, 2) try to walk as far as possible in that six-minute time frame, and 3) at any 
time you can stop to rest or sit in one of the chairs, but we ask that you keep walking as 
soon as you feel able.  The participants were asked to walk alone unless gait imbalances 
required them to have a CES near to assist them.  At every minute, participants were told 
the time remaining and a standard verbal encouragement such as “Great job” was given.  
One CES kept track of the time on a stopwatch and placed a mark on the data collection 
sheet every time the participant completed one length of the hallway.  At the end of the 
test, participants were asked to stop where they were and a CES marked on the wall 
where they had stopped.  The CES measured the partial distance the participant had 
covered from the end of the hallway to the spot on the wall with a meter stick.  This 
value was added to the total distance of lengths completed to ensure a precise 
measurement of the distance covered.  At the end of the test HR, BP, RPE and SpO2 
values were recorded immediately by a CES.   
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 The distance and variables such as age, height, weight, FVC and FEV1 were used 
to calculate predicted VO2peak from four well established prediction equations: 1) VO2peak 
= 0.03 x distance (m) + 3.98 (Cahalin et al., 1996), 2) VO2peak = 0.02 x distance (m) – 
0.191 x age (yrs) – 0.07 x weight (kg) + 0.09 x height (cm) + 0.26 x (RPP x 10^-3) + 
2.45 (Cahalin et al., 1996), 3) VO2peak = 0.02 + distance (m) - 0.14 x age (yrs) - 0.07 x 
weight (kg) + 0.03 x height (cm) + 0.23 x (RPP x 10^-3) + 0.10 x FEV1(L) – 1.19 x FVC 
(L) + 7.77 (Cahalin et al., 1996), and 4) VO2peak = 4.948 + 0.023 x distance (m) (Ross et 
al., 2010). 
Statistical Analysis 
 A power analysis was conducted using the statistical program G-power (Version 
3.1) prior to the study to determine the appropriate sample size for significance.  For both 
protocols a repeated measures ANOVA was utilized to examine the differences in 
VO2peak obtained by the UNCCRI treadmill protocol against the VO2peak values 
determined by the four 6MWT prediction equations.  Paired t-tests were utilized to test 
the differences in HR and SBP between the UNCCRI protocol and the 6MWT protocol.  
A Pearson r-correlation between values obtained using the UNCCRI treadmill protocol 
and 6MWT equations 1-4 were run to determine the strength of the relationship in 
VO2peak.  Significance was set to p < 0.05.  All statistical analyses were conducted using 
the Statistical Package for the Social Sciences software package (SPSS, Chicago, IL). 
Results 
Participant Characteristics 
 Table 3 displays the cancer types, and Table 4 displays age, height, weight, and 
FVC/FEV1 for study participants.  Table 5 displays all resting characteristics for 
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participants prior to each test.  The participants were comprised of 49 males and 79 
females with a mean age of 62 ± 14 years, a mean height of 169 ± 8 cm, and a mean 
weight of 78 ± 20 kg.  Mean FVC was 3.44 ± 0.89 L and mean FEV1 was 2.59 ± 0.72 L.  
Mean resting heart rate (RHR), systolic blood pressure (RSBP), and diastolic blood 
pressure (RDBP) before the UNCCRI treadmill test were 82 ± 14 bpm, 125 ± 15 mmHg 
and 75 ± 9 mmHg, respectively.  The mean RHR, RSBP, and RDBP before the 6MWT 
was 78 ± 14 bpm, 123 ± 13 mmHg and 74 ± 8 mmHg, respectively.  There was a 
significant difference observed between RHR before the treadmill and before the 6MWT 
(p = 0.003).  There was no significant difference observed in RSBP (p = 0.137) and in 
RDPB (p = 0.419) prior to each test.  Twenty four percent of the CS were undergoing 
chemotherapy and/or radiation treatments during testing.  All participants completed each 
of the VO2peak protocols without complications. 
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Table 3 
Cancer Types 
Cancer Type N 
Breast 51 
Prostate 19 
Lymphoma/Leukemia 12 
Colon 12 
Lung 7 
Skin 6 
Ovarian 5 
Renal 5 
Uterine 3 
Sarcoma 3 
Pancreatic 3 
Esophageal 2 
Multiple Myeloma 2 
Rectal 2 
Thyroid 1 
Ampullary 1 
Oroparyngeal 1 
Stomach 1 
Neuroendocrine 1 
             
  
Table 4 
Age, Weight, Height, FVC, FEV1 
Age 62 ± 14 
Weight (kg) 78 ± 20 
Height (cm) 169 ± 8 
FVC (L) 3.44 ± 0.89 
FEV1 (L) 2.59 ± 0.72 
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Table 5  
Resting Characteristics  
UNCCRI TM 6MWT P-value 
RHR (bpm) 82 ± 14 78 ± 14 0.003* 
RSBP (mmHg) 125 ± 15 123 ± 13 0.137 
RDBP (mmHg) 75 ± 9 74 ± 8 0.419 
 
Note: RHR = resting heart rate; RSBP = resting systolic blood pressure; RDBP = resting 
diastolic blood pressure; *denotes a p-value < 0.05. 
 
 
Table 6  
Mean Peak Exercise Values  
UNCCRI TM 6MWT P-Value 
HR (bpm) 150 ± 21 109 ± 21 <0.001* 
SBP (mmHg) 150 ± 18 139 ± 20 <0.001* 
DBP (mmHg) 77 ± 10 75 ± 9 0.013* 
RPE 9 ± 2 6 ± 2 <0.001* 
SO2 (%) 94 ± 3 95 ± 3 <0.001* 
TM Time (min) 10.5 ± 2.9 - - 
Walk Distance (m) - 499 ± 101 - 
 
Note: HR = heart rate; SBP = systolic blood pressure; DBP = diastolic blood pressure; 
RPE = rate of perceived exertion; *denotes significant differences between groups. 
 
Validity of Predicted VO2peak for the 6MWT 
Table 6 summarizes predicted peak oxygen consumption values of the UNCCRI 
treadmill test and the 6MWT.  Average time spent on the treadmill was 10.5 ± 2.9 
minutes and the average distance walked during the 6MWT was 499 ± 101 meters (m).  
6MWT peak HR (109 ± 21 bpm), SBP (139 ± 20 mmHg), DPB (75 ± 9 mmHg), and 
RPE (6 ± 2) were significantly lower (p < 0.05) compared to the UNCCRI treadmill 
protocol peak HR (150 ± 21 bpm), SBP (150 ± 18 mmHg), DPB (77 ± 10 mmHg), and 
RPE (9 ± 2).  Oxygen saturation during the 6MWT was significantly higher (95 ± 3) than 
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the UNCCRI protocol (94 ± 3) (p < 0.001).  The UNCCRI protocol yielded a 
significantly higher VO2peak of 24.7 ± 7.4 mL/kg/min compared to all four 6MWT 
prediction equations (p<0.001).  Figure 1 displays the mean VO2peak values for the 
UNCCRI treadmill protocol and all four 6MWT prediction equations.  Equations 1, 2, 3 
and 4 yielded VO2peak values of 18.9 ± 3.0, 14.2 ± 4.6, 8.3 ± 3.8, and 16.4 ± 2.3 
mL/kg/min, respectively.   
Correlation Analyses 
Figures 2-5 display correlations between the UNCCRI treadmill protocol and all 
four VO2peak prediction equations.  Positive strong correlations occurred between the 
UNCCRI treadmill protocol and 6MWT prediction equation 1 (r = 0.83) and equation 4 
(r = 0.83).  Moderately strong correlations occurred between the UNCCRI treadmill 
protocol and 6MWT equation 2 (r = 0.74) and equation 3 (r = 0.70). 
 
 
Figure 1.  Mean VO2peak values. * denotes a significant difference (p < 0.001) between 
the 6MWT prediction equation and the UNCCRI treadmill VO2peak value.   
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Figure 2. Correlation between UNCCRI Treadmill VO2peak and 6MWT prediction 
Equation 1 VO2peak. 
 
 
 
 
 
Figure 3. Correlation between UNCCRI Treadmill VO2peak and 6MWT prediction 
Equation 2 VO2peak. 
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Figure 4. Correlation between UNCCRI Treadmill VO2peak and 6MWT prediction 
Equation 3 VO2peak. 
 
 
 
 
Figure 5. Correlation between UNCCRI Treadmill VO2peak and 6MWT prediction 
Equation 4 VO2peak. 
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Discussion 
The aim of this study was to assess the validity of predicted VO2peak from the 
6MWT compared to the UNCCRI treadmill protocol in a cancer specific population.  It 
was hypothesized that VO2peak predicted from the 6MWT equations would be 
significantly lower than VO2peak obtained from the UNCCRI treadmill protocol.  This 
was confirmed with the UNCCRI protocol yielding significantly higher VO2peak values (p 
< 0.001) compared to all four 6MWT prediction values. Other studies have cautioned 
using 6MWT VO2peak prediction equations in populations where individual monitoring is 
crucial due to the variability in VO2peak values (Maldonado-Martin et al., 2006; Ross et 
al., 2010).  Although Equation 1 was found to have a strong correlation with the 
UNCCRI protocol (r = 0.83), the differences between VO2peak values were significant (p 
< 0.001), concluding that this trend isn’t representative of validity.  Maldonado-Martin et 
al. (2006) investigated Equation 1 and questioned the validity of using the walk test to 
determine functional capacity in elderly patients with heart failure (HF).  In their study, 
the measured VO2peak was 13.5 ± 2.9 (mL/kg/min) while the prediction equation using 
6MWT distance significantly overestimated VO2peak (17.2 ± 3.3; p < 0.05).  The 
researchers concluded that predicting VO2peak results in substantial variability and should 
not be used in HF patients where an accurate determination of functional capacity is 
essential.  Ross et al. (2010) reviewed several studies and determined an equation to 
predict VO2peak from 1083 patients with diverse cardiopulmonary disease diagnoses.  
Although a moderate correlation (r=0.59) was found between distance covered and 
predicted VO2peak, the standard estimation of error (SEE) was unacceptably large (3.82 
mL/kg/min) for clinical usefulness in individual patients.  They state that their prediction 
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equation, like other prediction equations, is of limited usefulness for individual patients.  
Like other disease populations, validity of functional capacity is imperative in CS. 
 Moderate to strong correlations were seen between the UNCCRI VO2peak value 
and 6MWT VO2peak values from Equation 1 (r = 0.83) and Equation 3 (r = 0.70).  The 
correlations, although strong, do not validate the 6MWT because significant differences 
(p < 0.001) were observed between the UNCCRI protocol and Equations 1-4.  Several 
studies found similar positive correlations between VO2peak measured during a CPET 
compared to VO2peak during the 6MWT (Cahalin et al., 1996; Faggiano et al., 1997; 
Guazzi et al., 2009; Jehn et al., 2009; Zugck et al., 2000).  In 37 patients with varying 
classifications of heart failure, a good positive correlation (r = 0.72) was overall seen 
between the 6MWT VO2peak and from a CPET VO2peak (Jehn et al., 2009).  However, 
when these patients were grouped according to their VO2peak, the correlation was highly 
dependent on the functional impairment of the subjects.  In subjects with a VO2peak 
greater than 25.2 mL/kg/min, the 6MWT VO2peak was significantly lower than the CPET 
test (23.4 ± 2.6 vs. 27.6 ± 3.3).  On the other hand, those with a VO2peak equal to or lower 
than 17.5 mL/kg/min, the 6MWT VO2peak was significantly higher than the CPET test 
(15.5 ± 3.6 vs. 13.6 ± 2.5).  It has been suggested that these data should be taken into 
careful consideration when using the 6MWT to evaluate clinical prognosis in patients 
with varying degrees of clinical disability (Jehn et al., 2009).   
Other studies have reported similar results that at higher levels of functional 
capacity the 6MWT should not be used as a measure of VO2peak (Deboeck et al., 2014; 
Fujino et al., 2015; Lipkin et al., 1986).  Lipkin et al. (1986) found that maximal CPET 
tests may be more appropriate for patients who have mild HF, or a VO2 of greater than 
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20 mL/kg/min.  On average, the CS in the current study had a VO2peak over this threshold 
and it is concluded that a maximal CPET is more appropriate in CS.  Even for the CS 
under this threshold, a maximum CPET was found to be more appropriate than the 
6MWT.  Deboeck et al. (2014) stated that a distance greater than 500m during the 
6MWT results in the test becoming less sensitive to increases in VO2peak.  The average 
distance walked for our CS was 499m, which implies that one should be careful to 
interpret 6MWT VO2peak as valid.  Fujino et al. (2015) found a significant correlation in 
VO2peak (r = 0.55, p < 0.01) for distances below 450m, but no correlation with distances 
greater than 450m (r = 0.304, p = 0.193).  Several other studies report that there is not a 
significant correlation between the 6MWT VO2peak and a CPET VO2peak in healthy and 
elderly populations who have higher degrees of functional capacity compared to chronic 
disease populations (Deboeck et al., 2014; Green et al., 2001; Gremeaux et al., 2008).  In 
healthy individuals, and those who may have early stage clinical disease or relatively 
high functional capacity, the 6MWT may not be suitable for evaluating exercise capacity 
(Jones, Eves, Haykowsky, Joy, & Douglas, 2008; Schmidt et al., 2013).  The American 
Thoracic Society states that although investigators have used the 6MWT in clinical 
settings, this does not prove that the test is clinically useful or the best test for 
determining functional capacity (American Thoracic Society, 2002).  The 6MWT itself 
can only estimate VO2peak, and the information provided by the 6MWT should be 
considered complimentary to CPET but not a replacement for it. 
 All participants were able to safely complete both protocols with no significant 
adverse events.  In CS, the 6MWT produced significantly lower heart rate values than the 
UNCCRI treadmill protocol (109 ± 21 bpm vs. 150 ± 21 bpm, respectively).  This 
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supports the conclusion that the 6MWT in a cancer specific population is a submaximal 
protocol and should not be used to assess VO2peak.  Other studies have demonstrated 
similar results with significant differences in heart rate values between the walk test and a 
CPET test for several disease and healthy populations (Blanco et al., 2010; Cavalheri et 
al., 2016; Deboeck et al., 2014; Green et al., 2001; Gremeaux et al., 2008; Zugck et al., 
2000).  Contrary to these results, other researchers found that the walk test elicited a 
maximal exercise response in participants with a low VO2peak, questioning the test as a 
submaximal protocol in other disease populations (Faggiano et al., 1997; Jehn et al., 
2009).  Faggiano et al. (1997) found the walk test to be questionable as a submaximal test 
in HF populations because 73% of subjects were above anaerobic threshold at 
termination.  Lower HR values during the 6MWT are likely seen because the participant 
sets their own pace.  It was uncommon to find CS putting in maximum effort, even when 
the stated goal of the test is to walk as far as possible in that time frame.  This was also 
demonstrated by the results of the RPE for participants.  For the UNCCRI treadmill 
protocol the RPE averaged 9 ± 2 and the walk test only averaged 6 ± 2 on a scale of 0-10.  
The treadmill requires participants to undergo increased intensities until they reach their 
maximum effort, while the 6MWT is purely subjective.  The test is self-paced and 
motivation is a large factor that can account for up to 30% of the variability (Enright, 
2003).  Although some CS may prefer a submaximal test because of treatment-related 
side effects, a treadmill protocol may be necessary to help factor out motivation levels.  
The significant difference seen between RHR before the treadmill and before the walk 
test is likely due to the CS being apprehensive about a treadmill test.     
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It was hypothesized that the multivariate prediction equations taking into account 
individual differences in height, weight and other physiologic variables would have a 
higher correlation with the UNCCRI treadmill protocol.  The correlation found between 
Equation 3 and the UNCCRI protocol was actually lower (r = 0.70) compared to 
Equation 1 and the UNCCRI protocol (r = 0.83).  Equation 3 had a lower correlation with 
the UNCCRI protocol most likely due to this equation being derived from a cardiac, not 
cancer specific, population.  These results demonstrate that these specific equations 
cannot be used to accurately assess VO2peak in a cancer specific population. 
Limitations and Future Directions 
 There were several limitations to this study.  First, the hallway distance at the 
UNCCRI was only 12.6 meters and a longer hallway may have increased final distance 
due to the participants not having to turn around as often (Beekman et al., 2013).  
However, course length has been shown to not significantly affect the results of the 
6MWT with courses greater than 15 meters (Sciurba et al., 2003; Weiss, 2000).  Second, 
gas analysis was not utilized in either test to confirm VO2peak results, although the 
UNCCRI protocol has been validated in a prior study using gas analysis (r = 0.93) 
(Shackelford et al., 2015).  Third, CS already enrolled at the UNCCRI have previously 
undergone UNCCRI treadmill assessments and the familiarity with the protocol 
compared to the 6MWT could allow them to perform at a higher level.  Last, motivation 
levels could have been affected by the CES assisting with the protocols if the participant 
was already enrolled at the UNCCRI and had been familiar with them and their training 
style.  For future research, a longer track and gas analysis during both protocols might be 
suggested to strengthen statistical significance and validity.  Future studies might also 
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provide the necessary data for equations to be developed that could more accurately 
assess VO2peak from the 6MWT in CS.  Although a small portion of this study, those 
participants who utilized the handrails during the treadmill protocol had less significant 
differences in VO2peak during the treadmill and 6MWT prediction Equation 1.  This trend 
should be further investigated to see if the 6MWT is more accurate in CS who have to 
utilize the handrails during a treadmill assessment.   
Conclusion 
This study assessed the validity of predicting VO2peak from the 6MWT compared 
to the UNCCRI treadmill protocol in a cancer specific population.  Findings suggest that 
the 6MWT is not a valid test for predicting VO2peak in CS due to the fact that all four 
6MWT prediction equations significantly underestimated VO2peak in CS.  Our results 
demonstrate that CS can safely complete maximal protocols for the best VO2peak value.  
Other studies have concluded that cancer survivors can safely complete peak 
cardiopulmonary exercise testing (De Backer et al., 2007; Jones et al., 2007; Kilka et al., 
2009; May et al., 2010).  Even those CS with limited functional capacity who needed to 
utilize the handrails could do so with accurate results.  The 6MWT may be favored 
because of the limited exercise capacity often seen in CS, but shouldn’t be substituted as 
an assessment tool in CS for VO2peak.  The completion of a maximal assessment provides 
more precise results that lead to more accurate prescription intensities to progress 
exercise capacity safely over the course of rehabilitation.  It is proposed that cancer 
rehabilitation clinics do not use the 6MWT to evaluate VO2peak, and to instead use the 
UNCCRI treadmill protocol to obtain VO2peak.   
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APPENDIX B 
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APPENDIX C 
 
UNIVERSITY OF NORTHERN COLORADO 
CANCER REHABILITATION INSTITUTE 
TREADMILL PROTOCOL 
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Client Name: _____________________________ Client ID #:_________________      
Date:__________________________ 
 
Prior to testing take resting HR, BP, and Weight 
Date of Birth:_________________     Age: ________ Phase: __________  RHR:  ___________ RBP:  __________      
Est. HR Max: _____ 
 
Body Weight (lbs):)_________                Kg (lbs/2.2:) ________ Is this the same data acquired from an initial 
assessment/reassessment? Y N  
 
RMCRI Cancer Treadmill Protocol Worksheet 
Stage Speed Grade Time BP HR RPE SpO2 
0 1.0mph 0% 1 min     
1 1.5mph 0% *   
2 2.0mph 0% *   
3 2.5mph 0% *     
4 2.5mph 2% *   
5 3.0mph 2% *   
6 3.3mph 3% *     
7 3.4mph 4% *   
8 3.5mph 5% *   
9 3.6mph 6% *     
10 3.7mph 7% *   
11 3.8mph 8% *   
12 3.9mph 9% *     
13 4.0mph 10% *   
14 4.1mph 11% *   
15 4.2mph 12% *     
16 4.3mph 13% *   
17 4.4mph 14% *   
18 4.5mph 15% *     
19 4.6mph 16% *   
20 4.7mph 17% *   
Cool-
Down 
** 
0% 
*     
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*Identify time for each the final stage and for the cool-
down.  **Identify speed for cool-down. 
Note: If client changes from a walk to a run during this test, identify the time when 
the gait changed. 
 
Was the client holding the handrails?   Yes No 
 Was the client running during the last stage completed?      Yes No If Yes, 
what time did running start: _____________  
 
VO2 Peak (L/Min) : ____________     VO2 Peak (mL/kg/min) : _____________     
Peak RER: ________ Max HR:__________ 
 
FINAL TIME to peak/volitional fatigue: _____________________  as a decimal 
(minutes . (sec/60))___________________ 
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APPENDIX D 
SIX MINUTE WALK TEST PROTOCOL 
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Six Minute Walk Test Data Collection 
 
Client Name: ________________________    Client ID #:______________   Date: 
_________ 
Date of Birth: ______________           Age: ______                              Phase: 
_____   
RHR: __________    RPB: __________   Est. HR Max: 
_________   
Body Weight (lbs):_________ Body Weight (kg):___________ Height (ft., 
in.)____________ 
FEV1 (L):___________     FVC (L):____________ Height (cm):____________ 
Equipment needed for test:     two stethoscopes      two BP cuffs      pulse ox       HR 
monitor    
     sticky notes   measuring stick  two portable chairs  
 stopwatch 
Place a mark for 
every length of the 
hallway completed 
 
 
Total number of hall lengths walked: _________________ 
Partial length distance: ______________________(ft, in.)  
After Completion of the Test: 
HR:________  BP:_________  RPE:_________   SPO2 ________________ 
 
Conversions:   1in = 2.54 cm                    12 in = 1 foot                   1m = 100cm  
1 meter = 3.28 feet       39.37 inches = 1 meter   RPP= SBP x HR 
 
Hallway Distance: 1 length = 12.6 meters 
 
Total Lengths Walked: ______________ * 12.6 = ________________ meters  
Partial Length Distance: ___________ (ft, in.) = ____________ inches = ___________ 
meters 
Total Distance Walked (m) = (# of lengths*12.6m) + partial distance (m) 
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_____________ total lengths walked (m)  +  ______________ partial distance (m) = 
 
 
Total Distance Walked (m) = _________________ 
 
 
Cahalin Equation 1: 
Peak VO2 = 0.03 x distance (m) + 3.98 
 
Peak VO2 = 0.03 x _________ (m) + 3.98 
 
Peak VO2 (mL/kg/min):_____________ 
 
 
Cahalin Equation 2: 
Peak VO2=0.02 x distance(m) – 0.191 x age(yr) – 0.07 x weight(kg) + 0.09 x 
height(cm) + 0.26 x RPP x 10-3 + 2.45 
 
Peak VO2=0.02 x ________ (m) – 0.191 x _____ (yr) – 0.07 x ______ (kg) + 0.09 x 
_______(cm) + 0.26 x _________(RPP) x 10-3 + 2.45                                
 
Peak VO2 (mL/kg/min):_____________ 
 
 
Cahalin Equation 3: 
Peak VO2=0.02 x distance(m) - 0.14 x age(yr) – 0.07 x weight(kg) + 0.03 x height(cm) 
+ 0.23 x RPP x 10-3 + 0.10 x FEV1 (L) – 1.19 x FVC (L) + 7.77 
 
Peak VO2=0.02 x ________(m) - 0.14 x _______(yr) – 0.07 x _______(kg) + 0.03 x 
_______(cm) + 0.23 x ___________(RPP) x 10-3 + 0.10 x ______ (L) – 1.19 x 
_______(L) + 7.77 
 
Peak VO2 (mL/kg/min):______________ 
 
 
Ross Equation: 
Mean Peak VO2 = 4.948 + 0.023 * mean 6MWD (meters) 
Mean Peak VO2 = 4.948 + 0.023 * __________ (m) 
Peak VO2 (mL/kg/min):______________ 
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APPENDIX E 
 
ABBREVIATIONS 
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ACSM – American College of Sports Medicine 
ATS – American Thoracic Society 
BP – Blood Pressure 
CAD – Coronary Artery Disease 
CES – Cancer Exercise Specialist 
COPD – Chronic Obstructive Pulmonary Disease 
CPET – Cardiopulmonary Exercise Testing 
CRF – Cardiorespiratory Fitness 
CS – Cancer Survivor 
DBP – Diastolic Blood Pressure 
FEV1 – Forced Expiratory Capacity 
FVC – Forced Vital Capacity 
HF – Heart Failure 
HR – Heart Rate 
NCSLC – Nonsmall Cell Lung Cancer 
RDBP – Resting Diastolic Blood Pressure 
RER – Respiratory Exchange Ratio 
RHR – Resting Heart Rate 
RPE – Rate of Perceived Exertion 
RPP – Rate Pressure Product 
RSBP – Resting Systolic Blood Pressure 
SBP – Systolic Blood Pressure 
SEE – Standard Error of Estimation 
SPO2 – Blood Oxygen Saturation 
UNCCRI – University of Northern Colorado Cancer Rehabilitation Institute 
US – United States 
VO2max – Maximum Volume of Oxygen Consumption 
VO2peak – Peak Volume of Oxygen Consumption 
6MWT – Six Minute Walk Test 
 
 
